Bulevirtid (3) – Hepcludex®
Hepatitis delta virus (HDV) infection, HDV RNA-positive
Characteristics
| Start date | 01.06.2025 |
|---|---|
| Resolution | 18.06.2025 |
| INN | Bulevirtid |
| Brand name | Hepcludex® |
| Pharm. company | Gilead Sciences GmbH |
| G-BA Procedure ID | D-1205 |
| Therapeutic area | Infectious diseases Orphan |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Bulevirtid (4) | Hepcludex® | Gilead Sciences GmbH | Hepatitis delta virus (HDV) infection, HDV RNA-positive, aged ≥ 3 years, body weight ≥ 10 kg | 400–3,202 | 100% additional benefit not proven Orphan (turnover limit) | |
| Bulevirtid (3) | Hepcludex® | Gilead Sciences GmbH | Hepatitis delta virus (HDV) infection, HDV RNA-positive | n.d. | discontinued Orphan | |
| Bulevirtid (2) | Hepcludex® | Gilead Sciences GmbH | Hepatitis delta virus (HDV) infection, HDV RNA-positive, ≥ 3 to < 18 years, ≥ 10 kg bw | n.d. | discontinued Orphan | |
| Bulevirtid (1) | Hepcludex® | MYR GmbH | Chronic hepatitis Delta |
0
300–4,800 |
100% Hint for non-quantifiable additional benefit Orphan repealed |
<< List of all resolutions